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A B S T R A C T
The European Virus Archive (EVA) was created in 2008 with funding from the FP7-EU Infrastructure
Programme, in response to the need for a coordinated and readily accessible collection of viruses that could be
made available to academia, public health organisations and industry. Within three years, it developed from a
consortium of nine European laboratories to encompass associated partners in Africa, Russia, China, Turkey,
Germany and Italy. In 2014, the H2020 Research and Innovation Framework Programme (INFRAS projects)
provided support for the transformation of the EVA from a European to a global organization (EVAg). The EVAg
now operates as a non-proﬁt consortium, with 26 partners and 20 associated partners from 21 EU and non-EU
countries. In this paper, we outline the structure, management and goals of the EVAg, to bring to the attention of
researchers the wealth of products it can provide and to illustrate how end-users can gain access to these re-
sources. Organisations or individuals who would like to be considered as contributors are invited to contact the
EVAg coordinator, Jean-Louis Romette, at jean-louis.romette@univmed.fr.
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1. Introduction
The European Virus Archive (EVA) was created in 2008 with
funding from the FP7-EU Infrastructure Programme, in response to the
need for a coordinated and readily accessible collection of viruses that
could be made available to academia, public health organisations and
industry (Gould et al., 2012). Within three years, it developed from a
consortium of nine European laboratories to encompass associated
partners in Africa, Russia, China, Turkey, Germany and Italy. Following
the H2020, 2014 call for Research and Innovation Framework Pro-
gramme (INFRAS projects) the concept of developing the EVA into a
global organization was a natural progression and the project was
funded for a four-year period. In April 2015, the EVAg started to op-
erate as a non-proﬁt consortium including 26 partners and 20 asso-
ciated partners from 21 EU and non-EU countries. Based on excellent
progress during the ﬁrst two operational years, we have every reason to
believe that the consortium will continue to expand and will ultimately
constitute the world's largest virus collection. In this paper, we outline
the structure, management and goals of the EVAg, to bring to the at-
tention of researchers the wealth of products it can provide and to il-
lustrate how end-users can gain access to these resources.
2. History of virus archives
Laboratory isolation and characterisation of viral pathogens, such as
vaccinia virus, poliovirus, foot and mouth disease virus, yellow fever
virus and others, began at the turn of the twentieth century. This re-
presented a pioneering era in the development of medical and veter-
inary virology. Over the years, diagnostic and research centres were
established worldwide to investigate viruses causing a wide range of
diseases including those that had hitherto escaped all attempts to be
identiﬁed and cultured under laboratory conditions. In the 21st cen-
tury, ever-growing numbers of mammalian viruses continue to be iso-
lated. They may represent only the tip of the iceberg, as more viruses
are being discovered and reported using rapidly developing molecular
technologies.
As a result of these advances, the isolation, identiﬁcation, char-
acterisation and preservation of growing virus collections has inevitably
generated new challenges. Many of the known viruses are in collections
that may be lost or discarded when the virologist in charge retires or
when a laboratory closes or is reorganized. Other collections may not be
available to the wider virology community, because scientists are not
always willing or in a position to share their viral isolates. They may
lack the infrastructure, time (manpower), facilities and experience to
characterize and present their collection in an accessible catalogue and
further be able to ship their collected strains to foreign countries due to
the restraints imposed by increasingly complex transportation regula-
tions. Furthermore, many governments have introduced additional se-
curity measures that speciﬁcally regulate the transfer and/or exchange,
between countries, of high-risk-group pathogens that may attract the
interest of terrorist organisations. Additionally, laboratories in Russia,
China, India, Southeast Asia and South America hold their own virus
collections, many of which, to date, have been relatively inaccessible to
European laboratories. Viruses from many taxonomic families have also
been identiﬁed on the African continent and some well-developed la-
boratories in Africa have made their collections readily accessible to
researchers in Europe and the Americas. Currently, however, except for
a few countries, including Senegal, South Africa and Kenya, authenti-
cated virus collections from other regions of Africa are virtually non-
existent.
One objective of the EVAg therefore has been to establish trust
among these widely disparate institutes and to associate the scientists in
these countries with partners in the consortium under carefully mon-
itored conditions that protect these developing laboratories, to the
mutual beneﬁt of everyone. The current project aims at the develop-
ment of virus collections in low-income countries where, in some cases,
there has been an understandable reluctance to exchange viruses for
fear of losing their resource to institutes from more highly developed
countries. The EVAg infrastructure provides assured access to modern
capacities, thereby assisting these institutes to train their staﬀ in de-
veloping their own resources and expanding and maintaining these
capacities locally. End-user requests for viruses and reagents from these
developing laboratories will be entirely managed from within, but
supported by the quality management and distribution systems of the
consortium. In common with all other members of the consortium,
these developing laboratories will automatically retain full ownership
of their collections.
Elsewhere, research laboratories often accumulate collections of
viruses that are primarily dependent on the speciality of the laboratory
scientists. For example, the American Type Culture Collection (ATCC)
and the US Centres for Disease Control and Prevention (CDC) maintain
large collections of mammalian viral pathogens, including Risk Group 4
(RG4) agents. Laboratories in Russia, China, India, Southeast Asia,
South Africa, Australia and New Zealand hold collections that have
been isolated speciﬁcally in their countries. Relatively large collections
of arboviruses are currently held in the USA (Galveston National
Laboratory, Texas), France, the Czech Republic, Slovakia and also in
some countries of Scandinavia. European collections of speciﬁed animal
pathogens, particularly lyssaviruses, pestiviruses, arboviruses and in-
ﬂuenza viruses are maintained at the Animal and Plant Health Agency
and at The Pirbright Institute in the United Kingdom; in Italy at the
Istituto Zooproﬁlattico Sperimentale delle Venezie (IZSVe) hosting the
World Organization for Animal Health/Food and Agriculture
Organization (OIE/FAO) and EU reference laboratory for avian inﬂu-
enza; and in France at the Institut Pasteur. RG4 viruses such as Ebola
and Nipah are maintained in specialised facilities in France, Germany
Russia, the USA, China, South Africa and the UK. Diverse viruses of
medical or veterinary importance (coronaviruses, herpesviruses, retro-
viruses, adenoviruses, enteroviruses, etc.) are held in laboratories
around the world. As the EVAg continues to develop and to expand its
boundaries, access to a greater proportion of these viruses will be en-
abled where possible.
Recently, in meeting the challenges of emerging viruses, the con-
sortium has voluntarily oriented a part of its activities to the support of
the World Health Organization (WHO) during emerging health crises by
dedicating a new work-package entitled “Response to emergence”.
Moreover, the EVAg is currently an associated partner of the Global
Outbreak Alert and Response Network (GOARN).
3. The EVAg: a multilateral approach to archiving
Current processes of coordinating virus standardisation, character-
isation, preservation and distribution are inevitably relatively arbitrary,
and are largely dependent on the speciality of each laboratory. In fact,
besides the EVAg, we are unaware of any non-proﬁt organization that is
concerned with facilitating reliable access globally to viruses and as-
sociated reagents from individual virus collections for research and/or
diagnostic laboratories, teaching centres or industries involved in the
production of diagnostic reagents, pharmaceuticals and vaccines solely
for the beneﬁt of science, in a safe and carefully regulated manner. It
would be virtually impossible to establish a single laboratory to main-
tain supplies of all recognised pathogenic mammalian viruses. Based on
the knowledge and experience gained from the former EVA project, we
have addressed these problems by using web-based tools to centralise
access to quality-controlled, standardised preparations of viruses held
in laboratories worldwide. The underlying concept is simple, but be-
cause virologists are naturally protective of their collections, its success
has required a paradigm shift in the mind-set of the partners or asso-
ciated partners in the individual laboratories.
The H2020-INFRAIA-2014-2015 Framework programme of the
European Union (EU) placed a call for funding applications under the
heading “Research and Innovation Action,” with sub-headings, one of
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which was “Research Infrastructures.” Accordingly, the concept of the
EVAg was created and a funding proposal was submitted. In preparing
the proposal, it was emphasised that it would be virtually impossible to
generate a wide-ranging virus archive in a single laboratory complex.
Thus, although many high-calibre virology laboratories operate in
Europe, it was decided to retain the “virology club tradition” by de-
veloping the principle of an integrated international infrastructure via
consortia, operating through validated networks. As far as we are
aware, this concept had not previously been encompassed by virologists
in the context of producing and providing access to viruses.
The EVAg was therefore conceived to ﬁll the gaps in accessing
viruses through identiﬁcation of qualiﬁed international laboratories
that could become partners of the consortium. It was agreed that by
integrating their collections or resources and devising appropriate va-
lidated protocols and eﬀective dissemination procedures, the partner
laboratories would be able to achieve common high standards in pro-
ducing and supplying authenticated viruses to the scientiﬁc community,
both within and outside Europe. The EVAg is unique. It was conceived
to move beyond the current state of the art and provide access to the
largest collection of mammalian viruses and associated reagents in the
world to the global scientiﬁc community, to government health and
environmental departments, to higher education institutes and to in-
dustry, through appropriate information systems.
4. The EVAg organizational structure
The new approach was, in the ﬁrst instance, to integrate non-EU
partners as beneﬁciaries of the project. This was possible because the
rule of reciprocal beneﬁt was agreed: the non-EU partner provision
activity of material to an EU entity (research institute, health organi-
zation, animal health-care structure, etc.) was eligible for ﬁnancial
compensation from the consortium EU budget. Consequently, 26 high-
calibre European and non-European partner laboratories agreed to be-
come the primary members of the EVAg consortium. These are listed in
Table 1
Partner laboratories that form the core of the EVAg, listed in chronological order of their integration into the project. Both medical and veterinarian institutes are
included to cover viral zoonotic diseases. It also illustrates the wide geographic coverage already attained and demonstrates that BSL4 laboratories are major
contributors to this consortium. The choice of institutes also reﬂects the speciﬁc available skills and know-how of scientists in institutes closely associated with the
most well-known contemporary emerging viruses. We have also begun to integrate network organisations such as the Global Approach to Biological Research,
Infectious diseases and Epidemics in Low-income countries (GABRIEL) Network, of the Fondation Merieux and the International Pasteur Institutes. Future plans
include expansion of partnerships to countries not currently represented, such as Malaysia, Vietnam, Cambodia, Indonesia, South America, and additional African
countries.
Participating organization Country Contact person
Université d’Aix-Marseille (AMU) Partner #1 France Prof. Jean-Louis Romette: jean-louis.romette@univ-
amu.fr
Unité des Virus Emergents-AMU, IRD190, INSERM 1207 (UVE) France Prof. Xavier de Lamballerie:
Xavier.De-Lamballerie@univ-amu.fr
Architecture et Fonction des Macromolécules Biologiques - UMR 7257 (AFMB) France Dr. Bruno Coutard:
Bruno.coutard@afmb.univ-mrs.fr
Bernhard Nocht Institut fuer Tropenmedizin (BNI) Germany Prof. Stephan Günther: guenther@bni-hamburg.de
The Secretary of State for The Department of Environment, Food and Rural Aﬀairs
(DEFRA/APHA)
United Kingdom Prof. Tony Fooks:
Tony.Fooks@apha.gsi.gov.uk
Department of Health (DH-PHE) – Special Pathogens (Virology) Laboratory United Kingdom Dr Miles Carroll:
Miles.Carroll@phe.gov.uk
Universitaet Basel (UNIBAS), Department Biomedicine – Petersplatz Switzerland Prof Daniel Pinschewer: daniel.pinschewer@unibas.ch
Univerza V Ljubljani (UL) Slovenia Prof. Tatjana Avsic-Zupanc: tatjana.avsic@mf.uni-lj.si
Virologicky ustav Slovenskej Akademie vied (IVSAS) Slovakia Dr. Boris Klempa: boris.klempa@savba.sk
Istituto Nationale per le Malattie Infettive L.Spallanzani I.R.C.C.S. (INMI) Italy Dr. Maria Rosaria Capobianchi: maria.capobianchi@
inmi.it
Robert Koch Institut (RKI) Germany Dr. Andreas Nitsche:
NitscheA@rki.de
Erasmus Universitair Medisch Centrum Netherlands Prof. Marion Koopmans: m.koopmans@erasmusmc.nl
Academish Ziekenhuis Leiden – Leids Univesitair Medish Centrum (LUMC) Netherlands Dr. Alexander Gorbalenya:
A.E.Gorbalenya@lumc.nl
Institute National de la Santé et de la Recherche Médicale (INSERM) France Dr. Hervé Raoul: herve.raoul@inserm.fr
Institut Pasteur (IP) France Dr. Hervé Bourhy: herve.bourhy@pasteur.fr
Friedrich Loeﬄer Institut – Bundesforschungsinstitut fuer tierges sundheit (FLI) Germany Prof. Thomas Mettenleiter
ThomasC.Mettenleiter@ﬂi.de
The Pirbright Institute LBG (TPI) United Kingdom Dr Carrie Batten:
Carrie.batten@pirbright.ac.uk
Agricultural Research Council (ARC-OVI) South Africa Dr. Claude Sabeta:
SabetaC@arc.agric.za
National Institute for Communicable Diseases of the National Health Laboratory Services,
(NICD-NHLS)
South Africa Prof. Janusz Tadeusz Paweska: januszp@nicd.ac.za
Chumakov Institute of Poliomyelitis and Viral Encephalitides (IPVE) Russian Federation Dr. Alexander Lukashev: alexander_lukashev@
hotmail.com
Scientiﬁc Research Institute of Inﬂuenza of the ministry of healthcare of the Russian
federation (RII)
Russian Federation Prof. Mikhail Y. Eropkin: eropkin@inﬂuenza.spb.ru
I.I Mechnikov Scientiﬁc Research Institute for Vaccines and Sera (Mechnikov RIVS) Russian Federation Prof. Vitaly V. Zverev: zverev@bioservice.ru
Wuhan Institute of Virology (WIV) China (People's Republic
of)
Prof. Zhihong Hu: huzh@wh.iov.cn
Commonwealth Scientiﬁc and Industrial Research Organization (CSIRO) - Australian
Animal Health Laboratory (AAHL)
Australia Dr. Sam Mc Cullough: sam.mccullough@csiro.au
Folkhalsomyndigheten (FOHM) Sweden Dr. Ali Mirazimi:
Ali.Mirazimi@folkhalsomyndigheten.se
Fondation Mérieux (FMER) France Dr. Florence Pradel: ﬂorence.pradel@fondation-
merieux.org
Charite - Universitaetsmedizin Berlin (CUB) Germany Prof. Dr. Christian Drosten: christian.drosten@charite.
de
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Table 1.
In addition, 16 associate partners who share the same interest in the
dissemination of viruses and reagents, but are not beneﬁciaries of the
EU grant, have now been included (see Table 2). This association was
formalized by the signature of a Memorandum of Understanding. The
archive is founded on the principle that members and associate mem-
bers of the consortium retain ownership of the viruses that they dis-
seminate via the centralised distribution centre. The virologist or in-
stitution that supplies the viruses to the customer retains the ownership
and enters into agreements with the customer via material transfer
agreements (MTAs). All orders for viruses and associated reagents (cell
cultures, recombinant proteins, RNA, DNA, recombinant viruses, plas-
mids, monoclonal antibodies), are placed via the website https://www.
european-virus-archive.com/which is managed centrally in Marseille
by the Management team (partner#1, Aix-Marseille University).
During the early stages of the existence of the original EVA, em-
phasis was placed on establishing the collections of viruses and asso-
ciated reagents and ensuring that quality control was managed cen-
trally. This ensured that all laboratories complied with identical
standards. This principle has been further developed in the project. A
manager was appointed to head up a Management Quality Committee
with the responsibility of establishing and maintaining appropriate
standards through close monitoring of procedures, protocols and record
maintenance. To ensure uniformity throughout the consortium, the
quality managers representing each partner form the body of the
committee.
Previously, non-EU participants were given the status of associate
partners, i.e. they were associated with the consortium, but were not
full members. The objective was to evaluate the feasibility of this ap-
proach concerning both the collaborative exchanges related to devel-
opment of a common infrastructure and the operational eﬀectiveness of
resource distribution. From the point of view of scientiﬁc collaboration,
the process was established rapidly and functioned eﬃciently.
However, standardisation of the procedure for the distribution of ma-
terials to end-users proved to be challenging, and it is still being de-
veloped and improved within the current consortium. The reason for
this slow progress is almost entirely due to the complexity of national
regulations. Whilst the European Regulations retain the principle of
being national and are enforced primarily to control the circulation of
pathogens, they have been developed to maintain uniformity
throughout the EU countries. Thus, the administrative pathway to ob-
taining authorisation for an exchange of resources between, for
example, France and Germany or the Netherlands and Italy are very
similar and are principally based on agreements provided by the
National Biosafety Agencies. In contrast, the process of exchanging
resources between the EU and Russia or between the EU and the USA
involves many more constraints: the intervention of diﬀerent adminis-
trations in processing authorisation for delivery of hazardous goods
including, biosafety agencies, customs administration, commerce and
trade administration, ministry of health, etc. (Also, the law in Russia
does not permit the import or export of pathogens.) Nevertheless, our
expertise in overcoming these hurdles is exempliﬁed by the report of
studies on the RG4 virus Crimean-Congo haemorrhagic fever virus in
which the virus was supplied by a European partner to an end-user in
the USA (Haddock et al., 2018). Not surprisingly, when Zika virus
emerged in South America and was found to be responsible for mi-
crocephaly, we received numerous requests for Zika virus, and many
papers have been published with recognition of the EVAg as the source
of virus. Five examples encompassing, i) simultaneous transmission
with chikungunya virus, ii) diagnosis, iii) signal processing pathways,
iv) pathogenesis in relation to foetal infections and v) virus structure,
are cited here (Goertz et al., 2017; Chan et al., 2017; Zhang et al., 2016;
Miner et al., 2016; Sirohi et al., 2016).
These anticipated problems of transporting pathogenic viruses be-
tween countries, particularly outside Europe, were considered during
the preparation of the project. Each potential barrier to eﬃcient ex-
changes between diﬀerent countries was extensively discussed and
product dissemination objectives for each non-EU partner were deﬁned
depending on their speciﬁc status.
Once established and operating satisfactorily, the management team
continued the process of contacting high-calibre laboratories outside
Europe, organising meetings and conferences with these laboratories
and subsequently inviting them to become associate partners. Currently
associate partnerships have been negotiated and agreed with labora-
tories in Africa, Russia, China, Turkey, Australia, Japan, Germany,
Italy, Hungary, South Korea, South East Asia and South America
(Table 2). The initiation and early progress of the EVAg are already
tremendous achievements, and subject to its continued success and
expansion, it is anticipated that it will become the largest global net-
work of laboratories contributing to the sharing of resources and pro-
moting advances in virology.
Table 2
Currently agreed Associate Partners in the EVAg. The integration of institutes that share the same interest in research and in the provision of high quality products to
the scientiﬁc community is made through an association formalized by the signature of a Memorandum of Understanding. The choice of the Associate Partners has
been established to ﬁll gaps or to extend the list of viruses currently oﬀered in the catalogue, and to have EVAg present in geographical areas concerned by emerging
virus outbreaks.
Participating organization Country Contact person
Centre for Molecular Diagnostics and Therapy (CRIE) Russia Prof German Shipulin: shipulin@pcr.ru
St Petersburg Pasteur Institute Russia Dr Natalia Romanenkova: poliospb@nr3854.spb.edu
Hacettepe University, Faculty of Medicine (HU) Turkey Prof Koray Ergunay: ekoray@hacettepe.edu.tr
Hellenic Pasteur Institute (HPI) Greece Dr.Urania Georgopoulou: uraniag@pasteur.gr
Jordan University of Science and Technology (JUST) Jordan Prof. Dr. Nabil Hailat: hailatn@just.edu.jo
Les Centres Gheskio (GHESKIO) Haiti Dr. Jean W. Pape: jwpape@gheskio.org
University of Texas Medical Branch (UTMB) USA Prof Scott Weaver: sweaver@utmb.edu
Institut für Virologie (UMR-DE) Germany Prof. Dr. Stephan Becker:
Becker@staﬀ.uni-marburg.de
Centre d'Infectiologie Charles Mérieux de Bamako (CICM) Mali Prof. Bourema Kouriba: bourema.kouriba@cicm-mali.org
Centre Pasteur du Cameroun (CPC) Cameroun Dr. Richard Njouom: njouom@pasteur-yaounde.org
National Institute of Infectious Diseases (NIID) Japan Dr. Masayuki Saijo: msaijo@niid.go.jp
Istituto Zooproﬁlattico Sperimentale delle Venezie (IZSVe) Italy Dr. Maria Serena Beato: msbeato@izsvenezie.it
Institut Pasteur du Cambodia (IPC) Cambodia Dr. Didier Fontenille: dfontenille@pasteur-kh.org
Institut Pasteur de Madagascar (IPM) Madagascar Prof. André Spiegel: aspiegel@pasteur.mg
Institut Pasteur du Senegal (IPD) Senegal Dr Amadou Alpha Sall:
Amadou.SALL@pasteur.sn
Institut Pasteur d’Algérie (IPA) Algérie Dr Zoubir Harrat: zharrat@gmail.com
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5. Resources, management and access for end-users
Dissemination of resources including know-how and material to the
scientiﬁc community is one of the major deliverable of the project. It
has been addressed by the creation of web-based catalogue accessible
on the EVAg portal. Quality of the oﬀer is a key factor to diﬀerentiate
EVAg from the other infrastructures proposing similar products to the
end-user. The gold standard products listed on the catalogue have been
clearly at the origin of the fast growing dissemination activity of the
consortium and of its robust reputation as reliable provider of key
components for the detection of emerging viruses acting under the
umbrella of international health organisations.
5.1. Viruses and reagents available through the EVAg catalogue
The EVAg infrastructure provides wide-ranging and eﬃcient access
to virus collections held in laboratories worldwide, with the potential
for access to recently isolated viruses from clinical, veterinary and ﬁeld
samples. The collection will continually expand, as the number of
contributing laboratories increases and will provide participants with
access to materials and capacities, including:
• freeze-dried viruses for long-term storage;
• viruses validated by sequencing, including the “rescue” and char-
acterisation of archived material;
• reagents and kits, including primer sequences and appropriate
protocols for virus identiﬁcation;
• standardised diagnostic kits and recombinant proteins representing
genes of the viruses, or hyperimmune antisera with deﬁned speci-
ﬁcities;
• custom-prepared kits, proteins and antibodies;
• high-quality associated research laboratories accessible to perform
experiments and theoretical and practical training.
Relevant information can be obtained by placing an enquiry on the
website (www.european-virus-archive.com/evag-portal). At the time of
writing the catalogue shows more than 2000 products consisting of
viruses and associated reagents. The list which is constantly increasing
includes human, animal, insect, ﬁsh and plant viruses of medical, ve-
terinary, academic, industrial and economic importance In addition, a
range of arthropod tissue culture cell lines, monoclonal antibodies,
recombinant protein expression systems, puriﬁed viral RNA, specialised
kits for diagnosis and custom-prepared proteins, can also be obtained
through the website.
5.2. Quality control, safety standards and bio security
The approach to Quality Management is directed by the project's
own Quality Standard, based upon Organization for Economic
Cooperation and Development (OECD) guidelines, and critically fo-
cusses on the acquisition, characterisation and storage of virus pro-
ducts. Each partner institute seeks to comply with this way of working
to harmonise laboratory processes across the consortium. The Quality
Manager conducts “Best Practice” audits to quantify improvement
progress. All facilities are inspected and regulated by their own national
bio safety authorities, and employ staﬀ trained in procedures compliant
with the requirements of the International Air Transport Association
(IATA) for the safe dispatch of potentially hazardous materials.
Trans-national access (TNA) ensures free of charge access to
European research infrastructures and the costs of the research, pro-
ducts and associated activities. This opportunity is open to all European
researchers and to some extent to researchers from non-EU countries.
TNA dispatches include regulatory documentation such as import/ex-
port permits, and a certiﬁcate of analysis (CoA) provided by the sup-
plying partner.
The EVAg project has established a grading system that deﬁnes virus
product quality ranked from 1 to 5, in which Grade 5 is the basic level,
described as partially sequenced to conﬁrm identity; not checked for
mycoplasma contamination; unknown infectivity; and stored frozen.
The “gold standard” is a fully sequenced virus, mycoplasma-free, with
deﬁned infectivity and lyophilised for long-term storage. Derived pro-
ducts such as proteins, nucleic acids or antigens are also prepared using
standardised protocols and checked for quality before storage or dis-
patch.
Security at the consortium institutes is maintained using CCTV, PIN-
coded passes and at remote sites, 24-h manned security/vehicle iden-
tiﬁcation. Entry into bio containment laboratories is strictly controlled.
Supply of products to the applicants operates via the TNA approach
deﬁned above, whereby research groups apply through the web portal
by submission of a completed request form. A successful application
must be justiﬁed by an explanation of scientiﬁc objectives, techniques
to be utilised/developed, list of named researchers, list of relevant
publications and conﬁrmation that appropriate expertise and facilities
to handle the virus are in place. A review of these criteria is carried out
by the project quality manager and a selection panel that includes ex-
ternal experts.
5.3. Management and dissemination of information
A team of scientists and administrators is dedicated to the man-
agement of the EVAg, to ensure continuity and to maximize eﬃciency.
Whilst the individual laboratories operate through the web-based cat-
alogue, they supply to the end-user only the viruses and products that
are held in their collections. The website is the main communication
tool with which to inform the end-user and to disseminate the products
through the dedicated portal. The portal is conceived as a user-friendly
marketplace that lists the viruses and associated reagents of each
partner. This web-based catalogue constitutes a single entry point to the
archived viruses and reagents. It provides access for end-users to place
any enquiry about products of interest through a commonly used e-shop
format.
Any end-user could be entitled to free access to the virus or asso-
ciated reagent(s). The provider of the requested item(s) receives ﬁ-
nancial compensation from the EU budget. EU support for free-of-
charge access provided to the end-user has as its main objective to fa-
cilitate access of the scientiﬁc community to high quality resources.
However, this is conditional on the excellence of the project which the
end-user aims to develop using the resource. An international panel,
consisting of independent experts, reviews the request for free access
and subject to approval the customer will receive the item without
charge, other than covering the cost of transportation. In the case of a
charge being required to supply the virus or reagent, the EVAg only
recovers the cost of production and transportation to the customer.
Free-of-charge access to end-users employed outside EU-member or EU-
associate states is limited to 20% of the total accesses provided in the
grant. In addition to core partners, the project also integrates associate
partners as an eﬃcient means of enlarging the collection of viruses and
reagents in the web-catalogue.
5.4. Resource distribution activity
Easy and eﬃcient access to the viruses and reagents and to the
service oﬀered to the scientiﬁc community is attracting increasing
numbers of requests for the products in the catalogue. In addition, the
quality of the products distributed and the assistance provided by the
management team to answer speciﬁc questions from scientists are es-
tablishing the EVAg as a key biological resource centre worldwide. It is
now a recognised entity acting under the umbrella of medical and ve-
terinarian international health organisations which include the WHO,
GOARN, OIE and the major Centres for Disease Control and Prevention
around the world which underpin the control of emerging viral dis-
eases.
J.L. Romette et al. Antiviral Research 158 (2018) 127–134
131
5.5. Access for end-users
To place an enquiry and receive a quotation for a product, open a
web browser and type in “EVAg.” Then click on Login/Register to
create an account. The online catalogue can then be accessed via the
Portal link on the home page. Products in the catalogue can be found by
typing in a keyword/and/or the appropriate taxonomic name. The ﬁl-
ters on the right hand side of the Portal can also be used to browse
through the products by category. The product(s) of interest should
then simply be added to an enquiry cart, and the enquiry form should
be completed. A Material Transfer Agreement (MTA) and a quotation
for the products and shipping costs will then be sent to the end-user.
The enquiry then becomes an order when the quote is accepted and the
MTA is signed. All enquiries are evaluated in terms of biosafety, and an
oﬃcial (signed and stamped) end-user qualiﬁcation form of the la-
boratory to receive and handle the products of interest is requested.
6. Contribution of the EVAg to the control of contemporary
emerging viral diseases
The emergence of SARS at the end of 2002 has clearly demonstrated
the lack of preparedness of countries to face emerging virus outbreaks.
When the concept of EVA was discussed in 2008, this aspect of the
consortium activity was clearly stated in the project submitted to the
European Commission. This was reinforced in the second project: EVAg,
submitted in 2013, with a contingency fund dedicated to support this
activity.
6.1. Emergence of MERS coronavirus (MERS CoV) in the Arabian
Peninsula
The emergence of the novel MERS-CoV in humans in Saudi Arabia
in 2012 provided an opportunity for consortium partners and members
of a European Epidemic Response Network to develop a precise and
rapid MERS CoV diagnostic tool, suitable for ﬁeld diagnosis under
emergency conditions (Corman et al., 2012). During December 2012,
the WHO recommended PCR assays as the method to detect the virus in
blood samples, and identiﬁed the EVAg as a reliable source for the
delivery of positive control reagents (WHO, 2018). To date more than
300 kits have been distributed worldwide, to 155 laboratories in 58
countries. This achievement demonstrated the capacity of the con-
sortium to mobilize high-calibre scientists capable of rapidly devel-
oping and supplying a technical solution to a high-level emergency si-
tuation involving human pathogenic agents. Another key feature of this
achievement was the eﬃciency of our logistics platform to distribute
the material worldwide under the demanding conditions prevailing at
the time.
6.2. Zika virus outbreak in South America
Zika virus emerged in French Polynesia and spread rapidly to South
America and the Caribbean, causing at least 500,000 clinical cases,
within the ﬁrst year according to PAHO/WHO estimates. On the 1st of
February 2016, WHO declared a Public Health Emergency of
International Concern (PHEIC) (see Ref 2). On the 8th of February, the
US Centre for Disease Control (USCDC) elevated its response to “level 1
activation” i.e. the highest level. Prior to May 2015, there were two
strains of Zika virus in the EVAg online catalogue. By the ﬁrst trimester
of 2016, at the peak of international concern, partners had added eight
more products of direct relevance to the emergency situation.
Since November, 2015, the EVAg has received 260 enquiries for
more than 400 products to be distributed in 30 countries. A total of 168
products were provided in February, 2016 alone, with the highest de-
mands in the USA, Singapore, Netherlands, Germany, France and
China. In its interim guidance for Zika virus laboratory testing (March
23, 2016), WHO identiﬁed the EVAg as the provider for PCR quality-
control material (Corman et al., 2016). This emergency situation and
the resulting need for a coordinated distribution logistic was very
challenging. Consequently, the management team introduced proce-
dures to alleviate the burden on partners and to improve product ac-
cess. This was achieved by establishing additional distribution hubs for
Zika virus products obtainable from: the Centre for Molecular Diag-
nostics and Therapy (CRIE), Moscow, Russia; Wuhan Institute of Vir-
ology (WIV), Wuhan, Southern China; National Institute of Infectious
Diseases (NIID), Tokyo, Japan. The management team also negotiated a
common Material Transfer Agreement (MTA), with industry on behalf
of all consortium members and a centralised exchange logistics plat-
form was established. This experience underlines the reality that an-
ticipation and preparedness are key components for an eﬀective re-
sponse to public health emergencies.
6.3. Yellow fever outbreak in South America
From December, 2016 through May, 2017 Brazil reported its largest
yellow fever (YF) outbreak in decades, with a total of 3240 suspected
cases and 435 deaths (Fischer et al., 2017), prompting widespread
yellow fever virus (YFV) vaccination campaigns and the need to dis-
tinguish between vaccine- and wild-type YFV-associated disease. Novel
multiplex real-time reverse transcription PCRs that diﬀerentiate be-
tween vaccine and American wild-type YFV were developed by con-
sortium partners in response to this outbreak and validated under ﬁeld
conditions (Fischer et al., 2017).
6.4. Integration of national Centres for Disease Control (CDCs) and RG4
biological safety laboratory networks
Centres for Disease Control (CDC) in countries play an important
role for the control of virus outbreaks by the collecting data and sam-
ples during the identiﬁcation phase of the pathogens. However the
academic research combined with material collections appears to be an
unavoidable actor for the preparedness and the control of an emerging
virus disease, each time a variant form or a new form of a pathogen is
responsible of it. Combining, in the same organization, CDC and high
calibre research laboratories was foreseen as the best solution to reach
both an eﬃcient control of the virus propagation and a preparedness for
the next outbreak.
At the same time, to cover the all range of pathogens from RG2 to
RG4 was only made possible by the constitution of a group of high
containment facilities within the organization.
Sixteen registered Biosafety Level-4 (BSL-4) laboratories, with the
resources to handle the highest risk HG4 pathogens and ﬁve CDCs are
partners or associate partners in the consortium. Each CDC contributes
directly to the management and control of emerging virus diseases,
under the umbrella of the WHO. The EVAg is also associated with the
Global Outbreak Alert and Response Network (GOARN) and is re-
cognised by GOARN as a supplier of high quality viruses and virus-
related reagents and resources.
During the 2014–16 Ebola virus epidemics in West Africa, all of the
BSL-4 institutes were directly involved in helping local authorities to
contain the epidemic. They all gained important experience in the
management of such health crises, collecting ﬁeld samples and isolated
relevant virus strains many of which are now characterised and stored
in the facilities of the EVAg BSL-4 partner at the Bernard Nocht Institute
in Hamburg, Germany. In addition, they addressed speciﬁc issues in-
volving management of the exchange of high risk pathogens and acti-
vation of platforms dedicated to oﬀering services to appropriate end-
users.
7. Current status and future of the EVAg
The consortium is now in its third year of existence under the
H2020 Framework Programme. Its ultimate objective is to become a
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permanent archive that provides access to a very wide range of viruses
and reagents globally. This will be achieved ﬁrstly, through extension
of the funding arrangements, secondly through further increasing the
range of contributors to the collection, and thirdly by bridging large
European or international infrastructures having activities related to
those of EVAg, including:
• European Research Infrastructure on Highly Pathogenic Agents
(ERINHA); https://cordis.europa.eu/project/rcn/97132_en.html
• Infrastructures for Insect Disease Vector Research and Control
(INFRAVEC); https://infravec2.eu/
• Biobanking and BioMolecular Resources Research Infrastructure
(BBMRI); http://www.bbmri-eric.eu/faq/
• Microbial Resource Research Infrastructure (MIRRI); https://www.
mirri.org/home.html
• Network for Prevention and Control of animal diseases (VetBioNet);
https://www.vetbionet.eu
7.1. Extension of the funding arrangements
It would be naive to suggest that the long-term survival of the
consortium will be straightforward. For example, its perpetuation will
require a continuous and increasingly large funding stream to meet the
almost restrictive costs of research, laboratory development and upkeep
in the face of newly emerging highly pathogenic viruses. Sustainability
is a key issue for such an infrastructure and the consortium plan will be
to remain a non-proﬁt organization.
The obvious consequence of this fundamental choice is to have ac-
cess to diversiﬁed sources of funding. The nations to which partners
belong will have to support the collection activities including infra-
structure management, as well as research concerning the development
of new tools necessary to keep the archiving process up to date. The
ﬁnancial support for all the actions involved in preparedness for
emerging viral diseases e.g., distribution of bio-resources to supply re-
agents to detect infected patients at local level will have to come from
government health departments but at the international level, from the
European Commission, charitable international health funding agencies
such as the Wellcome Trust Foundation, the Bill and Melinda Gates
Foundation, the WHO, the OIE. Future ﬁnancial planning also includes
the creation of a speciﬁc interface between the industrial sector and the
consortium. In the ﬁrst instance, this interface will explore bi-direc-
tional opportunities to organize scientiﬁc exchanges, priority access to
bio-resources including reference material development of diagnostic
services, validation of diagnostic assays and commercialization by in-
dustrial partners to the beneﬁt of both parties. Signed contracts of
collaboration will be facilitated, and procedures harmonized.
7.2. Expansion of the range of contributors to the collection
As noted above, the concept of the EVAg is unique. As far as we are
aware, there is no equivalent viral archive, nor does any other collection
provide the accessibility, reagent backup, sequence data, provenance,
quality control, and capacity to advertise, inform, negotiate and conduct
the entire transaction to the end-user via the web and internationally re-
gistered secure transportation companies The reputations, high quality,
experience and knowledge of the consortium partners, combined with the
integration of the European Commission infrastructure, will provide end-
users with opportunities to approach new ﬁelds of research in structural
viral genomics, evolutionary biology, control of infectious diseases, anti-
viral drug design, fundamental research, public and environmental health,
pathogenesis, immunology and a wide variety of associated disciplines.
Subsequently, subject to continuation of funding and the appropriate
justiﬁcation, the EVAg aims to extend the diversity of its disciplines to
encompass ﬁsh, plant, bacterial, fungal, protist and other currently un-
recognised viruses. This will be achieved ﬁrst through expansion within
the European Community, followed by integration of specialist
laboratories in the Americas, Russia, Asia, Southeast Asia, Australia and
Africa. The recently created African CDC will provide a unique opportu-
nity to establish strong links with public health institutes in Africa. The
substance of this relationship will be based on trust and mutual beneﬁt.
For instance, training workshops and staﬀ exchanges will be organized
with the objective of developing appropriate infrastructures that can be
directly integrated into the EVAg format and the levels of scientiﬁc ex-
pertise and quality and range of products that will justify their integration
into EVAg as full partners within the consortium.
7.3. Looking to the future: integration with European and internationally
established infrastructures
The EVAg provides a range of viruses and relevant reagents to end-
users engaged in a wide variety of established infrastructures. For in-
stance, the newly created EU infrastructure, INFRAVEC (European
Infrastructures for Insect Disease Vector Research and Control - https://
infravec2.eu/) supplies infectious vectors (e.g. mosquitoes and ticks) to
their end-users. The EVAg is closely associated with this activity, via the
provision of viruses that can infect the vectors. ERINHA (http://www.
erinha.eu/), a European Strategy Forum on Research Infrastructures
(ESFRI www.esfri.eu/), oﬀering access to high containment facilities to
industrial end-users for their preclinical trials including BSL4 patho-
gens, recommends EVAg as the provider of the viruses necessary for
their trials. BBMRI, another ESFRI, plans to create a service unit dedi-
cated to the provision of viruses and derived material from viruses.
EVAg is identiﬁed as the recommended supplier.
The EVAg contributes to the functioning of other EU infrastructures
involved in related research topics including zoonotic diseases, drug dis-
covery, vaccine development, viral epidemiology and emerging virus
diseases. These EU-funded projects include PREPARE (Platform for
European Preparedness Against (Re-) emerging Epidemics - https://cordis.
europa.eu/project/rcn/110174_en.html), COMPARE (Collaborative
Management Platform for detection and Analyses of (Re-) emerging and
foodborne outbreaks in Europe - http://www.compare-europe.eu/about),
EMERGE (Eﬃcient response to highly dangerous and emerging pathogens
at EU level - https://www.emerge.rki.eu/), Zikalliance (a multinational
and multidisciplinary research consortium coordinated by INSERM -
https://zikalliance.tghn.org/about/). As a future objective, one can ima-
gine the generation of links among all of these organisations to constitute a
“Life Science Infrastructure Cooperative” dedicated to virology-related
topics, in which the EVAg could play a central role.
For the long-term future, we are planning to establish closer colla-
borative links with other compatible scientiﬁc infrastructures by in-
itiating teaching and training programmes amongst younger scientists
to ensure that people of the right calibre will be able to undertake the
roles currently occupied by experienced but “maturing” scientists.
Indeed, one could envisage e-learning programmes being built into
diploma courses in universities.
As we continue our ambitious mission to build a scientiﬁc infra-
structure that can beneﬁt scientists operating in all areas of the viral
world, we recognise that other agencies and research teams can provide
valuable datasets, and analytical expertise from which disease inter-
vention strategies might be developed. Indeed, other compatible
agencies are approaching the consortium to share their resources and to
promote their activities through the consortium website. This is yet
another avenue that is being explored, based on the complementarities
of these parties with the existing group of partners.
At the time of writing, we are witnessing the massive impact of next-
generation sequencing technology that will undoubtedly continue to
evolve and provide even more discoveries, any one of which might then
be exploitable by a future larger and more comprehensive form of
agency. Since the ﬁrst recognition of viruses and our obsession with
trying to understand and control them, it has been an exciting time for
virologists. Long may the EVAg and its successors ensure that this is
always the case!
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